Physician profile

James Thomas Cail

Family Medicine · Oklahoma City, OK

NPI 1669403085

$3,001.76

in general payments reported to CMS, 2019-2025

38 companies · $33.80 in 2025

The $33.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$691.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $357.15 2019-2024 Invega Sustenna, Invega Trinza, Invega
Abbvie INC. $309.67 2022-2024 Vraylar
Otsuka America Pharmaceutical, INC. $305.90 2019-2024 Rexulti, Abilify Maintena, Abilify Asimtufii
Amgen INC. $304.24 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $162.97 2019-2020
Genentech USA, INC. $159.67 2019-2020
Novo Nordisk INC $126.15 2019-2020
Allergan, INC. $119.64 2020
Corcept Therapeutics $116.51 2019
Merck Sharp & Dohme LLC $79.02 2019-2021
Pfizer INC. $76.99 2019-2020
Lilly USA, LLC $73.62 2020
Sunovion Pharmaceuticals INC. $54.96 2019-2022
Antares Pharma, INC. $49.88 2019-2024 Xyosted
Bausch Health US, LLC $44.57 2019-2020
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Eisai INC. $44.40 2019-2020
Alkermes, INC. $42.95 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $42.67 2020
Stryker Corporation $41.40 2019
Astrazeneca Pharmaceuticals LP $37.73 2019
Astellas Pharma US INC $36.95 2019-2020
Neurocrine Biosciences, INC. $36.20 2021-2023 Ingrezza
Ironshore Pharmaceuticals INC. $33.82 2019
Exact Sciences Corporation $33.80 2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Teva Pharmaceuticals USA, INC. $32.76 2019-2022
Ibsa Pharma INC. $29.87 2020
Amarin Pharma, INC. $28.38 2019
Glaxosmithkline, LLC. $27.84 2023 Trelegy Ellipta
Adlon Therapeutics L.P. $27.21 2020
Shire North American Group INC $24.91 2019
Abbott Laboratories $24.10 2020
Indivior INC. $22.13 2022
Horizon Therapeutics Plc $19.89 2020
E.R. Squibb & Sons, L.L.C. $17.64 2024
Optinose US, INC. $17.46 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $16.79 2019
Sanofi-Aventis U.S. LLC $11.01 2019
Qol Medical, LLC $10.91 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Thomas Cail

$3,001.76

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Pharmaceuticals, INC
Context
The $33.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/75284/james-thomas-cail

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.